J
Jenny Byrne
Researcher at University of Nottingham
Publications - 45
Citations - 1599
Jenny Byrne is an academic researcher from University of Nottingham. The author has contributed to research in topics: Transplantation & Myeloid leukemia. The author has an hindex of 17, co-authored 45 publications receiving 1341 citations. Previous affiliations of Jenny Byrne include Nottingham City Hospital & Nottingham University Hospitals NHS Trust.
Papers
More filters
Journal ArticleDOI
The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts
Camille N. Abboud,Ellin Berman,Adam D. Cohen,Jorge E. Cortes,Daniel J. DeAngelo,Michael W. Deininger,Steven M. Devine,Brian J. Druker,Amir T. Fathi,Elias Jabbour,Madan Jagasia,Hagop M. Kantarjian,Jean Khoury,Pierre Laneuville,Richard A. Larson,Jeffrey H. Lipton,Joseph O. Moore,Tariq I. Mughal,Susan O'Brien,Javier Pinilla-Ibarz,Alfonso Quintás-Cardama,Jerald P. Radich,Vishnu Reddy,Charles A. Schiffer,Neil P. Shah,Paul J. Shami,Richard T. Silver,David S. Snyder,Richard Stone,Moshe Talpaz,Ayalew Tefferi,Richard A. Van Etten,Meir Wetzler,Elisabetta Abruzzese,Jane F. Apperley,Massimo Breccia,Jenny Byrne,Francisco Cervantes,Ekaterina Chelysheva,Richard E. Clark,Hugues de Lavallade,Iryna Dyagil,Carlo Gambacorti-Passerini,John M. Goldman,Ibrahim C. Haznedaroglu,Henrik Hjorth-Hansen,Tessa L. Holyoake,Brian J. P. Huntly,Philipp le Coutre,Elza Lomaia,Francois-Xavier Mahon,David Marin-Costa,Giovanni Martinelli,Jiri Mayer,Dragana Milojkovic,Eduardo Olavarria,Kimmo Porkka,Johan Richter,Philippe Rousselot,Giuseppe Saglio,Güray Saydam,Jesper Stentoft,Anna G. Turkina,Paolo Vigneri,Andrey Zaritskey,Alvaro Aguayo,Manuel Ayala,Israel Bendit,Raquel Bengió,Carlos Best,Eduardo Bullorsky,Eduardo Cervera,Carmino DeSouza,Ernesto Fanilla,David Gómez-Almaguer,Nelson Hamerschlak,José A. López,Alicia Magarinos,Luis Meillon,Jorge Milone,Beatriz Moiraghi,Ricardo Pasquini,Carolina Pavlovsky,Guillermo J. Ruiz-Argüelles,Nelson Spector,Christopher Arthur,Peter Browett,Andrew Grigg,Jianda Hu,Xiao-Jun Huang,Timothy P. Hughes,Qian Jiang,Saengsuree Jootar,Dong-Wook Kim,Hemant Malhotra,Pankaj Malhotra,Itaru Matsumura,Junia V. Melo,Kazunori Ohnishi,Ryuzo Ohno,Tapan Saikia,Anthony P. Schwarer,Naoto Takahashi,Constantine S. Tam,Tetsuzo Tauchi,Kensuke Usuki,Jianxiang Wang,Fawzi Abdel-Rahman,Mahmoud Aljurf,Ali Bazarbachi,Dina Ben Yehuda,Naeem Chaudhri,Muheez A. Durosinmi,Hossam Kamel,Vernon J. Louw,Bassam Francis Matti,Arnon Nagler,Pia Raanani,Ziad Salem +118 more
TL;DR: There is a need to (1) lower the prices of cancer drugs to allow more patients to afford them and (2) maintain sound long-term health care policies.
Journal ArticleDOI
Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial
Charles Craddock,Charles Craddock,Nadira Y. Jilani,Nadira Y. Jilani,Shamyla Siddique,Shamyla Siddique,Christina Yap,Christina Yap,Josephine Khan,Sandeep Nagra,Janice Ward,Paul Ferguson,Paul Ferguson,Peter Hazlewood,Peter Hazlewood,Richard Buka,Paresh Vyas,Oliver Goodyear,Eleni Tholouli,Charles Crawley,Nigel H. Russell,Jenny Byrne,Ram Malladi,Ram Malladi,John A. Snowden,Michael Dennis +25 more
TL;DR: AZA is well tolerated after transplantation and appears to have the capacity to reduce the relapse risk in patients who demonstrate a CD8+ T cell response to tumor antigens, although these observations require confirmation in a prospective clinical trial.
Journal ArticleDOI
Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia.
Eduardo Olavarria,Shamyla Siddique,Mike Griffiths,Sharon Avery,Jenny Byrne,Karen Piper,Anne Lennard,Lalit Pallan,Julie Arrazi,Jolanta B. Perz,Derville O'Shea,John M. Goldman,Jane F. Apperley,Charles Craddock +13 more
TL;DR: Adjunctive targeted therapy allows the kinetics of disease relapse after a reduced-intensity allograft to be manipulated and represents a novel strategy by which outcome may be improved in patients who undergo transplantation for CML and other leukemias.
Journal ArticleDOI
De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial
Richard E. Clark,Fotios Polydoros,Jane F. Apperley,Dragana Milojkovic,Christopher Pocock,Graeme N. Smith,Jenny Byrne,Hugues de Lavallade,Stephen G. O'Brien,Tony Coffey,Letizia Foroni,Mhairi Copland +11 more
TL;DR: TKI de-escalation is safe for most patients with excellent responses to TKI therapy, and is associated with improvement in symptoms, and are shown to maintain responses in patients with stable major molecular response.
Journal ArticleDOI
Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced-intensity conditioning compared with standard preparative regimens.
Jane Parker,Tariq Shafi,Antonio Pagliuca,Aleksandar Mijovic,Stephen Devereux,Michael Potter,H. Grant Prentice,Mamta Garg,John A. Liu Yin,Jenny Byrne,Nigel H. Russell,Ghulam J. Mufti +11 more
TL;DR: It is demonstrated that VUD or sibling allogeneic SCT following reduced‐intensity conditioning is feasible in high‐risk MDS patients considered unsuitable for standard transplantation and is associated with comparable 3·5 year DFS to those receiving conventional regimens.